Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRC01 in Relapsed or Refractory Large B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia
NCT04836507Phase 2Recruiting
- Sponsor
- Curocell Inc.
- Start
- Mar 2021
- Primary completion
- Aug 2030
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of anbalcabtagene autoleucel in diffuse large B-cell lymphoma (DLBCL), B cell acute lymphoblastic leukemia (B-ALL), sponsored by Curocell Inc.. Started Mar 2021; status: recruiting.
02
Drugs
anbalcabtagene autoleucel
03
Conditions
diffuse large B-cell lymphoma (DLBCL)B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT04836507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04836507.